Acne Vulgaris – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Acne Vulgaris - Pipeline Review, H2 2012', provides an overview of the Acne Vulgaris therapeutic pipeline. This report provides information on the therapeutic development for Acne Vulgaris, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acne Vulgaris. 'Acne Vulgaris - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
Acne Vulgaris Therapeutic Products under Development, Key Players in Acne Vulgaris Therapeutics, Acne Vulgaris Pipeline Overview, Acne Vulgaris Pipeline, Acne Vulgaris Pipeline Assessment
Summary
Global Markets Direct’s, 'Acne Vulgaris - Pipeline Review, H2 2012', provides an overview of the Acne Vulgaris therapeutic pipeline. This report provides information on the therapeutic development for Acne Vulgaris, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acne Vulgaris. 'Acne Vulgaris - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Acne Vulgaris.
- A review of the Acne Vulgaris products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Acne Vulgaris pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
- Identify and understand important and diverse types of therapeutics under development for Acne Vulgaris.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Acne Vulgaris pipeline depth and focus of Acne Vulgaris therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Acne Vulgaris Therapeutic Products under Development, Key Players in Acne Vulgaris Therapeutics, Acne Vulgaris Pipeline Overview, Acne Vulgaris Pipeline, Acne Vulgaris Pipeline Assessment
Introduction
Global Markets Direct Report Coverage
Acne Vulgaris Overview
Therapeutics Development
An Overview of Pipeline Products for Acne Vulgaris
Acne Vulgaris Therapeutics under Development by Companies
Acne Vulgaris Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Acne Vulgaris Therapeutics – Products under Development by Companies
Acne Vulgaris Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Acne Vulgaris Therapeutics Development
Photocure ASA
Valeant Pharmaceuticals International
GlaxoSmithKline plc
Cipher Pharmaceuticals Inc.
Galderma S.A.
Meda AB
Toyama Chemical Co. Ltd
Cosmo Pharmaceuticals S.p.A
XOMA Ltd.
Quest PharmaTech Inc.
Syntopix Group Plc
Foamix Ltd.
Funxional Therapeutics Ltd
AndroScience Corporation
NanoBio Corporation
Cutanea Life Sciences
Braintree Laboratories, Inc.
Maruho Co.,Ltd.
Lee's Pharmaceutical Holdings Limited
Ausio Pharmaceuticals, LLC
XBiotech USA, Inc.
Acne Vulgaris – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
FX125L - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Absorica - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CLS001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IDP-107 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASC-J9 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AUS-131 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Visonac - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XOMA 052 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drospirenone + Ethinyl Estradiol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Differin + Tetralysal - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CB-03-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Epiduo + Doxycycline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NB-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FXFM244 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SYN 1163 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Duac Low Dose - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DRM-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lappa Arctium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CD07223 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
5-AMINOLEVULINIC ACID-PHOTODYNAMIC THERAPY + ADAPALENE - DRUG PROFILE
Product Description
Mechanism of Action
R&D Progress
BLI1100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ozenoxacin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acnex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ANT-1207 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CD2475/101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JNJ 10229570-AAA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
M512101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
M108101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Azithromycin + Levamisole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SL017 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RA-18C3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug For Acne - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oplon Active Patch - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ARK-E021 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CD5789 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ZK-008 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acne Vulgaris Therapeutics – Drug Profile Updates
Acne Vulgaris Therapeutics – Discontinued Products
Acne Vulgaris Therapeutics - Dormant Products
Acne Vulgaris – Product Development Milestones
Featured News & Press Releases
May 27, 2012: Cipher Pharma Announces FDA Approval Of CIP-ISOTRETINOIN
Jan 13, 2012: Photocure Completes Enrollment In Visonac Phase IIb Study For Acne Treatment
Dec 21, 2011: Cipher Announces NDA Amendment For CIP-ISOTRETINOIN Accepted As Complete Response
Dec 21, 2011: XOMA Initiates Gevokizumab Phase II Study For Moderate To Severe Acne Vulgaris
Nov 23, 2011: Cipher Submits NDA Amendment For Cip-Isotretinoin
Jul 15, 2011: Photocure Initiates Enrollment Into Phase II Trial Of Visonac For Treatment Of Acne
Apr 27, 2011: Syntopix Provides Update On SYN1113
Apr 19, 2011: MEDA Files Marketing Authorization Application For Acnex In Europe
Oct 29, 2010: Cipher Completes Patient Enrolment In CIP-ISOTRETINOIN Phase III Safety Study
Aug 09, 2010: Fibrocell Science Submits Clinical Study Report To FDA For Phase II/III Trial Of Azficel-T In Acne Scarring
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products Under Development for Acne Vulgaris, H2 2012
Products under Development for Acne Vulgaris – Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Number of Products under Development by Companies, H2 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2012
Comparative Analysis by Late Stage Development, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Early Clinical Stage Development, H2 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012
Products under Development by Companies, H2 2012 (Contd..1)
Products under Development by Companies, H2 2012 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2012
Photocure ASA, H2 2012
Valeant Pharmaceuticals International, H2 2012
GlaxoSmithKline plc, H2 2012
Cipher Pharmaceuticals Inc., H2 2012
Galderma S.A., H2 2012
Meda AB, H2 2012
Toyama Chemical Co. Ltd, H2 2012
Cosmo Pharmaceuticals S.p.A, H2 2012
XOMA Ltd., H2 2012
Quest PharmaTech Inc., H2 2012
Syntopix Group Plc, H2 2012
Foamix Ltd., H2 2012
Funxional Therapeutics Ltd, H2 2012
AndroScience Corporation, H2 2012
NanoBio Corporation, H2 2012
Cutanea Life Sciences, H2 2012
Braintree Laboratories, Inc., H2 2012
Maruho Co.,Ltd., H2 2012
Lee's Pharmaceutical Holdings Limited, H2 2012
Ausio Pharmaceuticals, LLC, H2 2012
XBiotech USA, Inc., H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Acne Vulgaris Therapeutics – Drug Profile Updates
Acne Vulgaris Therapeutics – Discontinued Products
Acne Vulgaris Therapeutics – Dormant Products
Acne Vulgaris Therapeutics – Dormant Products (Contd..1)
LIST OF FIGURES
Number of Products under Development for Acne Vulgaris, H2 2012
Products under Development for Acne Vulgaris – Comparative Analysis, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Late Stage Products, H2 2012
Mid Clinical Stage Products, H2 2012
Early Clinical Stage Products, H2 2012
Discovery and Pre-Clinical Stage Products, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Route of Administration, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Molecule Type, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Global Markets Direct Report Coverage
Acne Vulgaris Overview
Therapeutics Development
An Overview of Pipeline Products for Acne Vulgaris
Acne Vulgaris Therapeutics under Development by Companies
Acne Vulgaris Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Acne Vulgaris Therapeutics – Products under Development by Companies
Acne Vulgaris Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Acne Vulgaris Therapeutics Development
Photocure ASA
Valeant Pharmaceuticals International
GlaxoSmithKline plc
Cipher Pharmaceuticals Inc.
Galderma S.A.
Meda AB
Toyama Chemical Co. Ltd
Cosmo Pharmaceuticals S.p.A
XOMA Ltd.
Quest PharmaTech Inc.
Syntopix Group Plc
Foamix Ltd.
Funxional Therapeutics Ltd
AndroScience Corporation
NanoBio Corporation
Cutanea Life Sciences
Braintree Laboratories, Inc.
Maruho Co.,Ltd.
Lee's Pharmaceutical Holdings Limited
Ausio Pharmaceuticals, LLC
XBiotech USA, Inc.
Acne Vulgaris – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
FX125L - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Absorica - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CLS001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IDP-107 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASC-J9 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AUS-131 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Visonac - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XOMA 052 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drospirenone + Ethinyl Estradiol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Differin + Tetralysal - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CB-03-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Epiduo + Doxycycline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NB-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FXFM244 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SYN 1163 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Duac Low Dose - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DRM-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lappa Arctium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CD07223 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
5-AMINOLEVULINIC ACID-PHOTODYNAMIC THERAPY + ADAPALENE - DRUG PROFILE
Product Description
Mechanism of Action
R&D Progress
BLI1100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ozenoxacin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acnex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ANT-1207 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CD2475/101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JNJ 10229570-AAA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
M512101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
M108101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Azithromycin + Levamisole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SL017 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RA-18C3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug For Acne - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oplon Active Patch - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ARK-E021 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CD5789 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ZK-008 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acne Vulgaris Therapeutics – Drug Profile Updates
Acne Vulgaris Therapeutics – Discontinued Products
Acne Vulgaris Therapeutics - Dormant Products
Acne Vulgaris – Product Development Milestones
Featured News & Press Releases
May 27, 2012: Cipher Pharma Announces FDA Approval Of CIP-ISOTRETINOIN
Jan 13, 2012: Photocure Completes Enrollment In Visonac Phase IIb Study For Acne Treatment
Dec 21, 2011: Cipher Announces NDA Amendment For CIP-ISOTRETINOIN Accepted As Complete Response
Dec 21, 2011: XOMA Initiates Gevokizumab Phase II Study For Moderate To Severe Acne Vulgaris
Nov 23, 2011: Cipher Submits NDA Amendment For Cip-Isotretinoin
Jul 15, 2011: Photocure Initiates Enrollment Into Phase II Trial Of Visonac For Treatment Of Acne
Apr 27, 2011: Syntopix Provides Update On SYN1113
Apr 19, 2011: MEDA Files Marketing Authorization Application For Acnex In Europe
Oct 29, 2010: Cipher Completes Patient Enrolment In CIP-ISOTRETINOIN Phase III Safety Study
Aug 09, 2010: Fibrocell Science Submits Clinical Study Report To FDA For Phase II/III Trial Of Azficel-T In Acne Scarring
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products Under Development for Acne Vulgaris, H2 2012
Products under Development for Acne Vulgaris – Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Number of Products under Development by Companies, H2 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2012
Comparative Analysis by Late Stage Development, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Early Clinical Stage Development, H2 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012
Products under Development by Companies, H2 2012 (Contd..1)
Products under Development by Companies, H2 2012 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2012
Photocure ASA, H2 2012
Valeant Pharmaceuticals International, H2 2012
GlaxoSmithKline plc, H2 2012
Cipher Pharmaceuticals Inc., H2 2012
Galderma S.A., H2 2012
Meda AB, H2 2012
Toyama Chemical Co. Ltd, H2 2012
Cosmo Pharmaceuticals S.p.A, H2 2012
XOMA Ltd., H2 2012
Quest PharmaTech Inc., H2 2012
Syntopix Group Plc, H2 2012
Foamix Ltd., H2 2012
Funxional Therapeutics Ltd, H2 2012
AndroScience Corporation, H2 2012
NanoBio Corporation, H2 2012
Cutanea Life Sciences, H2 2012
Braintree Laboratories, Inc., H2 2012
Maruho Co.,Ltd., H2 2012
Lee's Pharmaceutical Holdings Limited, H2 2012
Ausio Pharmaceuticals, LLC, H2 2012
XBiotech USA, Inc., H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Acne Vulgaris Therapeutics – Drug Profile Updates
Acne Vulgaris Therapeutics – Discontinued Products
Acne Vulgaris Therapeutics – Dormant Products
Acne Vulgaris Therapeutics – Dormant Products (Contd..1)
LIST OF FIGURES
Number of Products under Development for Acne Vulgaris, H2 2012
Products under Development for Acne Vulgaris – Comparative Analysis, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Late Stage Products, H2 2012
Mid Clinical Stage Products, H2 2012
Early Clinical Stage Products, H2 2012
Discovery and Pre-Clinical Stage Products, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Route of Administration, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Molecule Type, H2 2012
Assessment by Stage and Molecule Type, H2 2012